Aurora Cannabis

ACB

Market cap $210M

Marijuana stocks, even with their volatile behavior, still offer diverse investment opportunities. Not every sector or company deals directly with the plant, so investors see this as an opportunity to capitalize. Now, even with that said, MSO and companies that work directly with the plant tend to capture more market share. Also, they are usually the first to see a run in trading when the time comes.

Aurora Cannabis has had a terrible track record in recent years. Even if recent regulatory changes in the U.S. cause a new pot boom, Aurora is unlikely to capitalize on it.

NASDAQ | TSX: ACB Canada's Largest Global Medical Cannabis Company to Discuss Growth Strategy, Key Trends and Market Opportunities EDMONTON, AB, Feb. 17, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.

What is it about the cannabis industry that keeps investors searching for top marijuana stocks to buy? Cannabis started as one of the first waves of peace, love, and rebellion towards many cultural injustices. Today, those same principles are the foundation in spirit. But the evolution of legal cannabis changed the culture forever. In 2026, significant changes have occurred and continue to happen. We have a battle for who will take over, will it be corporate cannabis or will the true cul;tiovaots be able to take back the industry.

NASDAQ | TSX: ACB EDMONTON, AB, Feb. 12, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the company will ring the Nasdaq closing bell on Wednesday, February 18, 2026, at the Nasdaq MarketSite in New York's Times Square. The ceremony will be led by Aurora's CEO and Executive Chairman, Miguel Martin, alongside a representative of the company's Board of Directors, executive leadership team and other employees.

NASDAQ | TSX: ACB Launch reinforces Aurora's leadership position across key international markets  EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.

Aurora Cannabis beat Q3 earnings and sales estimates as medical cannabis momentum drove growth, but persistent consumer weakness pressured the stock outlook.

Aurora Cannabis Inc. reported in-line financial results for Q3-2026 with increasing revenue and free cash flow. The company will divest its plant propagation segment and focus on international growth with higher profit margins. The company reported lower revenue for consumer cannabis as it prioritizes its cannabis sales for medical and international markets.

Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript

NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has filed a prospectus supplement establishing a new at-the-market offering program (the "ATM Program") that allows the Company to issue and sell up to U.S.$100 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at the Company's discretion. The Company intends to use the net proceeds from the Offering for strategic and accretive purposes only, including for increased cultivation capacity and M&A.